摘要
补体活化的终产物C5b-9在多个肾脏疾病的发病机制中发挥着重要作用.C5b-9通过在肾小球毛细血管壁、肾小管、系膜区等结构以不同形式沉积介导肾脏损伤,并与组织损伤的严重程度及疾病的活动度相关,通过抑制C5b-9的形成可缓解蛋白尿等临床症状.目前C5抑制剂依库珠单抗已应用于临床中,其通过减少C5b-9在肾脏中的沉积、减轻肾组织损伤及改善肾功能,在一部分患者中取得了显著的效果.加强对C5b-9的认识将为补体相关性肾脏疾病的诊疗提供新的思路.本文总结了 C5b-9在多种肾脏疾病中发挥的作用及可能的治疗靶点.
Abstract
C5b-9,the end product of complement activation,plays an important role in the pathogenesis of several renal diseases.C5b-9 mediates renal injury by depositing in different forms in glomerular capillary walls,tubules,tunica albuginea,and other structures,and correlates with the severity of tissue damage and disease activity.Inhibiting the formation of C5b-9 can alleviate clinical symptoms such as proteinuria.Currently,the C5 inhibitor Eculizumab has been used in the clinic,and it has achieved remarkable results in some patients by reducing the deposition of C5b-9 in the kidney,reducing renal tissue damage,and improving renal function.Enhancing the understanding of C5b-9 will provide new ideas for the diagnosis and treatment of complement-associated renal diseases.This article summarizes the roles played by C5b-9 in various renal diseases and possible therapeutic targets.
基金项目
山西省卫生健康委"四个一批"科技兴医创新计划重点攻关专项(2021XM29)
NETL
NSTL
万方数据